Considering that inhibition of Pol ζ, Pol δ or REV3 is toxic to normal cells, and perhaps unlikely to provide a suitable therapeutic index in vivo, inhibitors specifically targeting REV1 or its interaction with POLD3 might be a promising avenue to pursue for the development of a new cancer therapy. The gene discussed is REV1; the disease is cancer.